|
1
|
Ferlay J, Shin HR, Bray F, Forman D,
Mathers C and Parkin DM: Estimates of worldwide burden of cancer in
2008: GLOBOCAN 2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Sasako M, Sakuramoto S, Katai H, Kinoshita
T, Furukawa H, Yamaguchi T, Nashimoto A, Fujii M, Nakajima T and
Ohashi Y: Five-year outcomes of a randomized phase III trial
comparing adjuvant chemotherapy with S-1 versus surgery alone in
stage II or III gastric cancer. J Clin Oncol. 29:4387–4393. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Bray F, Jemal A, Grey N, Ferlay J and
Forman D: Global cancer transitions according to the Human
Development Index (2008–2030): A population-based study. Lancet
Oncol. 13:790–801. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Tu SP, Jiang XH, Lin MC, Cui JT, Yang Y,
Lum CT, Zou B, Zhu YB, Jiang SH, Wong WM, et al: Suppression of
survivin expression inhibits in vivo tumorigenicity and
angiogenesis in gastric cancer. Cancer Res. 63:7724–7732.
2003.PubMed/NCBI
|
|
5
|
Blank S, Deck C, Dreikhausen L, Weichert
W, Giese N, Falk C, Schmidt T and Ott K: Angiogenic and growth
factors in gastric cancer. J Surg Res. 194:420–429. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Gerald D, Chintharlapalli S, Augustin HG
and Benjamin LE: Angiopoietin-2: An attractive target for improved
antiangiogenic tumor therapy. Cancer Res. 73:1649–1657. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Mitsuhashi N, Shimizu H, Ohtsuka M,
Wakabayashi Y, Ito H, Kimura F, Yoshidome H, Kato A, Nukui Y and
Miyazaki M: Angiopoietins and Tie-2 expression in angiogenesis and
proliferation of human hepatocellular carcinoma. Hepatology.
37:1105–1113. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Maisonpierre PC, Suri C, Jones PF,
Bartunkova S, Wiegand SJ, Radziejewski C, Compton D, McClain J,
Aldrich TH, Papadopoulos N, et al: Angiopoietin-2, a natural
antagonist for Tie2 that disrupts in vivo angiogenesis. Science.
277:55–60. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Stratmann A, Risau W and Plate KH: Cell
type-specific expression of angiopoietin-1 and angiopoietin-2
suggests a role in glioblastoma angiogenesis. Am J Pathol.
153:1459–1466. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Urbich C, Kuehbacher A and Dimmeler S:
Role of microRNAs in vascular diseases, inflammation, and
angiogenesis. Cardiovasc Res. 79:581–588. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Fish JE and Srivastava D: MicroRNAs:
Opening a new vein in angiogenesis research. Sci Signal. 2:pe12009.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Weng C, Dong H, Chen G, Zhai Y, Bai R, Hu
H, Lu L and Xu Z: miR-409-3p inhibits HT1080 cell proliferation,
vascularization and metastasis by targeting angiogenin. Cancer
Lett. 323:171–179. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Bai J, Zhang J, Wu J, Shen L, Zeng J, Ding
J, Wu Y, Gong Z, Li A, Xu S, et al: JWA regulates melanoma
metastasis by integrin alphaVbeta3 signaling. Oncogene.
29:1227–1237. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T))Method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Tomayko MM and Reynolds CP: Determination
of subcutaneous tumor size in athymic (nude) mice. Cancer Chemother
Pharmacol. 24:148–154. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Cai LM, Lyu XM, Luo WR, Cui XF, Ye YF,
Yuan CC, Peng QX, Wu DH, Liu TF, Wang E, et al: EBV-miR-BART7-3p
promotes the EMT and metastasis of nasopharyngeal carcinoma cells
by suppressing the tumor suppressor PTEN. Oncogene. 34:2156–2166.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kim HS, Lee KS, Bae HJ, Eun JW, Shen Q,
Park SJ, Shin WC, Yang HD, Park M, Park WS, et al: MicroRNA-31
functions as a tumor suppressor by regulating cell cycle and
epithelial-mesenchymal transition regulatory proteins in liver
cancer. Oncotarget. 6:8089–8102. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Chen D, Guo W, Qiu Z, Wang Q, Li Y, Liang
L, Liu L, Huang S, Zhao Y and He X: MicroRNA-30d-5p inhibits tumour
cell proliferation and motility by directly targeting CCNE2 in
non-small cell lung cancer. Cancer Lett. 362:208–217. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Tie J, Pan Y, Zhao L, Wu K, Liu J, Sun S,
Guo X, Wang B, Gang Y, Zhang Y, et al: MiR-218 inhibits invasion
and metastasis of gastric cancer by targeting the Robo1 receptor.
PLoS Genet. 6:e10008792010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Alajez NM, Lenarduzzi M, Ito E, Hui AB,
Shi W, Bruce J, Yue S, Huang SH, Xu W, Waldron J, et al: MiR-218
suppresses nasopharyngeal cancer progression through downregulation
of survivin and the SLIT2-ROBO1 pathway. Cancer Res. 71:2381–2391.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Uesugi A, Kozaki K, Tsuruta T, Furuta M,
Morita K, Imoto I, Omura K and Inazawa J: The tumor suppressive
microRNA miR-218 targets the mTOR component Rictor and inhibits AKT
phosphorylation in oral cancer. Cancer Res. 71:5765–5778. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Tatarano S, Chiyomaru T, Kawakami K,
Enokida H, Yoshino H, Hidaka H, Yamasaki T, Kawahara K, Nishiyama
K, Seki N and Nakagawa M: miR-218 on the genomic loss region of
chromosome 4p15. 31 functions as a tumor suppressor in bladder
cancer. Int J Oncol. 39:13–21. 2011.PubMed/NCBI
|
|
23
|
Ng EK, Chong WW, Jin H, Lam EK, Shin VY,
Yu J, Poon TC, Ng SS and Sung JJ: Differential expression of
microRNAs in plasma of patients with colorectal cancer: A potential
marker for colorectal cancer screening. Gut. 58:1375–1381. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Etoh T, Inoue H, Tanaka S, Barnard GF,
Kitano S and Mori M: Angiopoietin-2 is related to tumor
angiogenesis in gastric carcinoma: Possible in vivo regulation via
induction of proteases. Cancer Res. 61:2145–2153. 2001.PubMed/NCBI
|
|
25
|
Felcht M, Luck R, Schering A, Seidel P,
Srivastava K, Hu J, Bartol A, Kienast Y, Vettel C, Loos EK, et al:
Angiopoietin-2 differentially regulates angiogenesis through TIE2
and integrin signaling. J Clin Invest. 122:1991–2005. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ahmad SA, Liu W, Jung YD, Fan F, Wilson M,
Reinmuth N, Shaheen RM, Bucana CD and Ellis LM: The effects of
angiopoietin-1 and-2 on tumor growth and angiogenesis in human
colon cancer. Cancer Res. 61:1255–1259. 2001.PubMed/NCBI
|
|
27
|
Hashizume H, Falcón BL, Kuroda T, Baluk P,
Coxon A, Yu D, Bready JV, Oliner JD and McDonald DM: Complementary
actions of inhibitors of angiopoietin-2 and VEGF on tumor
angiogenesis and growth. Cancer Res. 70:2213–2223. 2010. View Article : Google Scholar : PubMed/NCBI
|
